Myriad Genetics reported revenue of $179.3 million for the quarter ended June 30, 2022, representing a 7% year-over-year increase excluding revenue from divested businesses and a 9% sequential increase from the first quarter of 2022. The company's diluted GAAP EPS was $(0.18) and adjusted EPS was $0.04 in the second quarter of 2022. The company updated its fiscal year 2022 financial guidance to reflect an additional $20 million investment in research and development, technology, and sales and marketing programs. The company ended the quarter with $283.6 million in cash, cash equivalents and investments.
Revenue of $179.3 million for the quarter ended June 30, 2022, with a 7% year-over-year increase excluding revenue from divested businesses.
Diluted GAAP earnings per share (EPS) of $(0.18) and adjusted EPS of $0.04 in the second quarter of 2022.
Fiscal year 2022 financial guidance updated to reflect an additional $20 million investment in research and development, technology, and sales and marketing programs.
Ended the quarter with $283.6 million in cash, cash equivalents and investments.
Myriad Genetics provided its fiscal year 2022 financial guidance, reiterating its revenue and gross margin guidance and updating its guidance for total operating expense and earnings per share. The company is increasing its fiscal year 2022 operating expense guidance by approximately $20.0 million and plans to make opportunistic incremental investments in research and development, technology and sales and marketing programs.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance